AB-1005 Delivery for Parkinson's Disease

(PIA Trial)

This trial explores a new method to deliver a medicine called AB-1005 to the brain for treating Parkinson's disease. Researchers aim to determine if this method speeds up and simplifies the delivery process while ensuring the correct amount of medicine reaches the brain. The study also tests the safety of this method for up to six months post-procedure. The trial seeks participants who have had Parkinson's for over 10 years and experience symptoms such as slow movement, muscle stiffness, or tremors. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

Research has shown that AB-1005 is generally well-tolerated by people with Parkinson's disease. In an earlier study, researchers administered a single dose of AB-1005 directly into the putamen, a part of the brain, and reported no serious side effects. This suggests the treatment is safe, with no major harmful effects linked to the gene therapy itself.

Researchers are excited about AB-1005 for Parkinson's Disease because it introduces a novel delivery method called convection-enhanced delivery (CED) combined with real-time imaging using iMRI. Unlike traditional treatments that primarily involve oral medications or deep brain stimulation, CED allows for direct delivery of the drug into the brain, potentially increasing precision and effectiveness. This method may improve targeting of the affected brain regions and minimize side effects, offering a promising alternative to existing therapies.

Studies have shown that AB-1005, an experimental gene therapy, can help improve movement problems in people with Parkinson's disease. In an 18-month study, patients experienced about 2.2 more hours each day of well-controlled symptoms, known as "Good ON" time. The therapy proved generally safe, with no serious side effects directly linked to it. Further research indicated that most patients maintained stable results over time and required less additional medication. This suggests that AB-1005 might help reduce movement issues related to Parkinson's disease. Participants in this trial will receive AB-1005 through a prescriptive infusion algorithm for standardized intraputaminal administration, monitored under iMRI.⁴⁵⁶⁷⁸